Anti-2019-nCoV(S1) – 2 (H4) antibody

Reference: PTXCOV-A514



Product type


Description of Anti-2019-nCoV(S1) - 2 (H4) antibody

About the product

Proteogenix has developed neutralizing antibodies against 2019-nCOV (as named by WHO when SARS-CoV-2 begun to spread). The Anti-2019-nCoV(S1)- 2(H4) antibody is an IgG1 isotype, especially targeting the S1 part of the Spike protein. This product is a human-origin monoclonal antibody expressed in a mammalian system, which has been validated in binding assays and infection assays. The molecular weight is 150 kDa.

About Spike : the target

The spike protein is a transmembrane viral fusion protein. Spike has a homotrimeric structure and each monomere is composed of two subunits: S1 and S2. The S1 part is carrying the Receptor Binding Domain (RBD), and the S2 part is responsible of the fusion of the virus with the cellular membrane. The RBD Part of S1 is binding the Angiotensin Converting Enzyme 2 (ACE2) in the organism.
Proteogenix launched a panel of antibodies against SARS-CoV-2 spike and the nucleocapsid. Every of them can recognize specifically SARS-CoV-2 antigens without cross reactivity with other human coronaviruses. The antibody H4, blocks the RBD of the viral spike protein from binding to the cellular receptor, ACE2. This antibody is completely competitive with ACE2 for binding to RBD. It can bind simultaneously with the Anti-2019-nCoV(S1) – 1 (B38) antibody as these two antibodies are binding RBD in a different site.
Neutralizing antibodies are very promising in antiviral defense against the coronavirus disease 2019 (COVID-19) pandemic. This product is suitable in all immunological methods. Research use only.

Product nameAnti-2019-nCoV(S1) - 2 (H4) antibody
Expression systemMammalian
Molecular weight150kDa
Buffer25 mM Tris-HCl pH 7.5, 5 mM NaCl
Delivery conditionDry ice
Storage condition4°C for short term; -20°c or -80°C for long term
Related ProductsRBD Domain,SARS-CoV-2 RBD of Spike protein, N501Y – B 1.1.7 lineage – UK Alpha Variant
PublicationsCerutti, H., Ricci, V., Tesi, G. et al. Large scale production and characterization of SARS-CoV-2 whole antigen for serological test development. J Clin Lab Anal. 2021; e23735. doi
NoteFor research use and in vitro diagnostic only. Not suitable for human use.
ClonalityMonoclonal Antibody


There are no reviews yet.

Be the first to review “Anti-2019-nCoV(S1) – 2 (H4) antibody”

Your email address will not be published.



Please select the country of delivery so that we can send you the quotation including shipping costs.

Thank you for your request! You will receive your quotation per e-mail in a few seconds.

If you did not receive your quotation, please check your spam folder.

Contact us to order

+33 (0)3 90 20 54 70

Write us